Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment

Taking inspiration from nature, the biomimetic concept has been integrated into drug delivery systems in cancer therapy. Disguised with cell membranes, the nanoparticles can acquire various functions of natural cells. The cell membrane-coating technology has pushed the limits of common nano-systems (fast elimination in circulation) to more effectively navigate within the body. Moreover, because of the various functional molecules on the surface, cell membrane-based nanoparticles (CMBNPs) are capable of interacting with the complex biological microenvironment of the tumor. Various sources of cell membranes have been explored to camouflage CMBNPs and different tumor-targeting strategies have been developed to enhance the anti-tumor drug delivery therapy. In this review article we highlight the most recent advances in CMBNP-based cancer targeting systems and address the challenges and opportunities in this field.

[1]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[2]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[3]  Jie He,et al.  Annual report on status of cancer in China, 2011. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[4]  Jia Wei,et al.  Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer , 2017, International journal of nanomedicine.

[5]  Junbai Li,et al.  Macrophage Cell Membrane Camouflaged Au Nanoshells for in Vivo Prolonged Circulation Life and Enhanced Cancer Photothermal Therapy. , 2016, ACS applied materials & interfaces.

[6]  Will Liao,et al.  The cellular and molecular origin of tumor-associated macrophages , 2014, Science.

[7]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[8]  Ronnie H. Fang,et al.  Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors , 2016, Theranostics.

[9]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[10]  P. Allavena,et al.  Cancer related inflammation: the macrophage connection. , 2008, Cancer letters.

[11]  Jinho Park,et al.  Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.

[12]  Haijun Yu,et al.  Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer. , 2016, ACS nano.

[13]  F. Claas,et al.  Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. , 1995, Blood.

[14]  Jennifer J. Lhost,et al.  Differential MHC class I expression in distinct leukocyte subsets , 2011, BMC Immunology.

[15]  B. Bao,et al.  Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review , 2013, Cancer and Metastasis Reviews.

[16]  Dezhi Ni,et al.  Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane. , 2015, Nanoscale.

[17]  K. Pienta,et al.  Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. , 2003, Cancer research.

[18]  Ping Gong,et al.  Cancer Cell Membrane-Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy. , 2016, ACS nano.

[19]  Zhen Gu,et al.  Anticancer Platelet‐Mimicking Nanovehicles , 2015, Advanced materials.

[20]  C. Röcker,et al.  Endo- and exocytosis of zwitterionic quantum dot nanoparticles by live HeLa cells. , 2010, ACS nano.

[21]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[22]  Ronnie H. Fang,et al.  Cell membrane-derived nanomaterials for biomedical applications. , 2017, Biomaterials.

[23]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[24]  Jing Qin,et al.  A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles , 2017, Drug delivery.

[25]  H. Möhwald,et al.  Permeation of macromolecules into polyelectrolyte microcapsules. , 2002, Biomacromolecules.

[26]  Wei Liu,et al.  Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles. , 2017, Journal of biomedical materials research. Part A.

[27]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[28]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[29]  L. Harker,et al.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. , 2000, Blood.

[30]  J. Deloach,et al.  Preparation of resealed carrier erythrocytes and in vivo survival in dogs. , 1981, American journal of veterinary research.

[31]  J. Schlom,et al.  Therapeutic cancer vaccines: current status and moving forward. , 2012, Journal of the National Cancer Institute.

[32]  Liangfang Zhang,et al.  Coating nanoparticles with cell membranes for targeted drug delivery , 2015, Journal of drug targeting.

[33]  W. Liu,et al.  Cancer Cell Membrane‐Coated Upconversion Nanoprobes for Highly Specific Tumor Imaging , 2016, Advanced materials.

[34]  Ronnie H. Fang,et al.  Nanoparticle‐Based Antivirulence Vaccine for the Management of Methicillin‐Resistant Staphylococcus aureus Skin Infection , 2016, Advanced functional materials.

[35]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[36]  Qiang He,et al.  Stem Cell Membrane-Coated Nanogels for Highly Efficient In Vivo Tumor Targeted Drug Delivery. , 2016, Small.

[37]  Christian Lubich,et al.  The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? , 2016, Pharmaceutical Research.

[38]  Wenping He,et al.  How Leucocyte Cell Membrane Modified Janus Microcapsules are Phagocytosed by Cancer Cells. , 2016, ACS applied materials & interfaces.

[39]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[40]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[41]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[42]  A. Kakkar,et al.  Platelets and cancer. , 2002, The Lancet. Oncology.

[43]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[44]  X. Guan,et al.  Cancer metastases: challenges and opportunities , 2015, Acta pharmaceutica Sinica. B.

[45]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[46]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[47]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[48]  Samir Mitragotri,et al.  Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.

[49]  Yaping Li,et al.  Bioinspired Nanoparticles with NIR‐Controlled Drug Release for Synergetic Chemophotothermal Therapy of Metastatic Breast Cancer , 2016 .

[50]  G. Parmiani,et al.  Tumour-released exosomes and their implications in cancer immunity , 2008, Cell Death and Differentiation.

[51]  C. Xie,et al.  Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. , 2016, Nanoscale.

[52]  Xingzhong Zhao,et al.  Antitumor Platelet‐Mimicking Magnetic Nanoparticles , 2017 .

[53]  A. Brand,et al.  Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. , 1981, Experimental hematology.

[54]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[55]  Jie He,et al.  Annual report on status of cancer in China, 2010. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[56]  Paolo Rebulla,et al.  Transfusion Medicine 2 Platelet transfusions , 2007 .

[57]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[58]  Joseph E Italiano,et al.  The biogenesis of platelets from megakaryocyte proplatelets. , 2005, The Journal of clinical investigation.

[59]  J. Mu,et al.  Grapefruit-Derived Nanovectors Use an Activated Leukocyte Trafficking Pathway to Deliver Therapeutic Agents to Inflammatory Tumor Sites. , 2015, Cancer research.

[60]  Pengcheng Zhang,et al.  Cancer Cell Membrane‐Coated Gold Nanocages with Hyperthermia‐Triggered Drug Release and Homotypic Target Inhibit Growth and Metastasis of Breast Cancer , 2020, Advanced Functional Materials.

[61]  Ronnie H. Fang,et al.  Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. , 2015, Nano letters.

[62]  Fei Wang,et al.  In Situ Capture of Bacterial Toxins for Antivirulence Vaccination , 2017, Advanced materials.

[63]  Liangfang Zhang,et al.  Cell membrane-camouflaged nanoparticles for drug delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[65]  Charles A. Janeway,et al.  Decoding the Patterns of Self and Nonself by the Innate Immune System , 2002, Science.

[66]  Venkatareddy Nadithe,et al.  Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges , 2016, Acta pharmaceutica Sinica. B.

[67]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[68]  Florian Lang,et al.  Erythrocyte programmed cell death , 2008, IUBMB life.

[69]  Qianqian Zhu,et al.  Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis. , 2017, ACS nano.

[70]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[71]  Ronnie H. Fang,et al.  'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. , 2013, Nanoscale.

[72]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[73]  G. Glinsky,et al.  MDA-MB-435 Human Breast Carcinoma Cell Homo- and Heterotypic Adhesion under Flow Conditions Is Mediated in Part by Thomsen-Friedenreich Antigen-Galectin-3 Interactions* , 2003, The Journal of Biological Chemistry.

[74]  E. Morse.  Platelet transfusions. , 1971, British medical journal.

[75]  O. Farokhzad.  Using ligands to target cancer cells. , 2012, Clinical advances in hematology & oncology : H&O.

[76]  Robert Franco,et al.  International seminar on the red blood cells as vehicles for drugs , 2012, Expert opinion on biological therapy.

[77]  Qiang He,et al.  Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy , 2015, Advanced healthcare materials.

[78]  C. Pitzalis,et al.  Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways. , 2006, Rheumatology.

[79]  Jing Qin,et al.  Exploiting macrophages as targeted carrier to guide nanoparticles into glioma , 2016, Oncotarget.

[80]  Ronnie H. Fang,et al.  Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery , 2014, Nano letters.

[81]  L. Gardner,et al.  Leukocyte extravasation: chemokine transport and presentation by the endothelium. , 2002, Blood.

[82]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[83]  Ronnie H. Fang,et al.  Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. , 2013, Nanoscale.

[84]  J. Hamilton,et al.  Neutrophils: important contributors to tumor progression and metastasis , 2015, Cancer and Metastasis Reviews.